Articles

COVID-19 therapy and vaccination: a clinical narrative review

Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio

Article Type

Review

Published

This review discusses how the SARS-CoV-2 pandemic has progressed and surged, and summarizes the safety and efficacy of the most used therapies and vaccines in the light of recent evidence.

Read more

Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Teresa Guilera, Juan Pablo Chart Pascual, Maria del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco

Article Type

Review

Published

In this review, the lurasidone development programme for adult and paediatric patients is described. In addition, the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited, pivotal clinical studies conducted on both adults and children are summarized, and several clinical cases are also presented.

Read more

Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis

Dhiraj Dhoot, Gaurav Kumar Jain, Mukesh Manjhi, Prashant Kesharwani, Namrata Mahadkar, Hanmant Barkate

Article Type

Original Research

Published

This study compares the rate and extent of serum and sebum concentration of super-bioavailable itraconazole and conventional itraconazole at different dosing to determine their efficacy and safety in patients with dermatophytosis.

Read more

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Article Type

Review

Published

This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.